Caladrius Biosciences Inc. (NASDAQ:CLBS) shares traded up 5.6% on Monday . The stock traded as high as $6.15 and last traded at $5.85, with a volume of 56,006 shares trading hands. The stock had previously closed at $5.54.

Several research analysts have weighed in on the company. Zacks Investment Research upgraded Caladrius Biosciences from a “hold” rating to a “strong-buy” rating and set a $6.75 target price on the stock in a research note on Tuesday. Maxim Group reiterated a “hold” rating on shares of Caladrius Biosciences in a research note on Friday, May 6th. HC Wainwright upgraded Caladrius Biosciences from a “neutral” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Friday, April 29th. Finally, Rodman & Renshaw upgraded Caladrius Biosciences to a “buy” rating in a research note on Saturday, April 30th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Caladrius Biosciences currently has a consensus rating of “Buy” and an average target price of $3.83.

The company’s 50 day moving average is $5.49 and its 200-day moving average is $6.16. The firm’s market capitalization is $34.53 million.

In related news, Director Eric Wei sold 87,500 shares of the business’s stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $0.60, for a total value of $52,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Caladrius Biosciences, Inc, formerly NeoStem, Inc, is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CSCs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.